Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03857100 · ClinicalTrials.gov registry record · NA

Improving Wisely - Polypharmacy

A NA study of Adverse Drug Event, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
11,000
Enrollment target
1
Study location

NCT03857100 is a NA study of Adverse Drug Event that has completed, run by Johns Hopkins University. The registered enrollment target is 11,000 participants, above the 4,379-participant average among 5 other Adverse Drug Event trials with a reported enrollment target (151% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03857100, a NA study of Adverse Drug Event, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
11,000 participants
Enrollment target
1
Study location

Study Summary

This is a randomized controlled trial that uses an audit and feedback intervention to alert primary care physicians who are outliers in one or more metrics related to high risk prescribing of participants' outlier status. Primary care physicians will be randomized to the intervention or control arm, except in California, where all outliers will be notified. The investigators will evaluate the impact of the intervention on prescribing patterns.

Conditions Studied

Interventions

  • OTHER Audit and feedback - letter and report

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 11,000 participants
Start Date 2019-01-04
Est. Completion 2021-01-30
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT03857100

The ClinicalTrials.gov registry entry for NCT03857100 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,379-participant average among 5 other Adverse Drug Event trials with a reported enrollment target (151% higher). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adverse Drug Event appearing as the primary indexed condition, and to 1 intervention - of which Audit and feedback - letter and report is the first listed.

NCT03857100 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03857100 about?

NCT03857100 is a clinical study titled "Improving Wisely - Polypharmacy". This is a randomized controlled trial that uses an audit and feedback intervention to alert primary care physicians who are outliers in one or more metrics related to high risk prescribing of participants' outlier status. Primary care physicians will be randomized to the intervention or control arm,...

What is the current status of trial NCT03857100?

This trial is currently completed. It is a NA study. The enrollment target is 11,000 participants. The study started on 2019-01-04. Estimated completion is 2021-01-30.

What conditions does trial NCT03857100 study?

This clinical trial studies the following conditions: Adverse Drug Event.

What interventions are being tested in trial NCT03857100?

The interventions under investigation include: Audit and feedback - letter and report (OTHER).

Who is sponsoring clinical trial NCT03857100?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03857100 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adverse Drug Event

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.